Inbrija Will Be an Inhaled "On Demand" Med for Parkinson's Disease

May 2019

Inbrija (in-BREE-jah) will be the first INHALED levodopa for adults with Parkinson's disease.

Think of Inbrija as a fast-acting "on demand" levodopa. It starts to work in about 10 minutes...and lasts about an hour.

Inbrija won't replace daily meds. Instead, it'll be used as needed to treat "off" episodes...when scheduled carbidopa/levodopa (Sinemet, etc) wears off between doses and symptoms (rigidity, tremor, etc) return.

Practical advice for a better career, with unlimited access to CE

Hospital Pharmacy Technician's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Med Safety Optimize the Appearance of Med Warnings to Help Them Get Noticed
Certification Watch for Changes to Pharmacy Tech Certification and Credentialing
Medication Errors Stop Errors Between Dexamethasone and Dexmedetomidine in Their Tracks
Women's Health Anticipate That Brexanolone Will Be Saved for Severe Postpartum Depression
Transitions of Care Catch Common Med Mishaps in Patients Transferring Out of ICU
Depression Find Out if Your Hospital Will Administer Spravato for Depression
Pumps Help Prevent Issues When a Patient With an Intrathecal Pump Is Admitted
Parkinson's Disease Inbrija Will Be an Inhaled "On Demand" Med for Parkinson's Disease
Ophthalmology Look for the New Rx Eye Drop Cequa for Dry Eyes
ADHD Expect to Hear About Psychosis With ADHD Stimulants

Inbrija Will Be an Inhaled "On Demand" Med for Parkinson's Disease

Practical advice for a better career, with unlimited access to CE

Table of Contents